Page last updated: 2024-11-13
cytosinine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
cytosinine: the nucleoside portion of blasticidin S; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 75905627 |
MeSH ID | M0251093 |
Synonyms (5)
Synonym |
---|
4-amino-1-(4-amino-2-oxo-(2h)-pyrimidinyl)-1,2,3,4-tetradeoxy-beta-d-erythro-hex-2-enopyranuronic acid |
1860-84-0 |
beta-d-erythro-hex-2-enopyranuronic acid, 4-amino-1-(4-amino-2-oxo-(2h)-pyrimidinyl)-1,2,3,4-tetradeoxy- |
cytosinine |
(2s,3s,6r)-3-amino-6-(4-amino-2-oxopyrimidin-1(2h)-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 2 (33.33) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.05
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.05) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |